August 3rd, 2021 3-5PM ET
Tuesday on The Robert Scott Bell Show:
Cuomo Demands Private Businesses Ban Unvaccinated Customers Most of the Empire State’s residents probably see the delta variant as a nuisance – but we suspect Gov Andrew Cuomo sees it as an exciting opportunity. Because in a press conference that carried the whiff of his daily briefings from the depths of the crisis last spring and summer, Gov. Cuomo asked private businesses in the state to enter “vaccine only admission”.“Private businessess…I am asking them, and suggesting to them…go to vaccine only admission,” Gov. Cuomo said. In another obviously political calculation, Cuomo made the statement hours after the local press reported that Mayor Bill de Blasio is reluctant to impose another mask mandate on the people of NYC (though the CDC has already imposed a mandate of its own). Clearly, Cuomo – who managed to survive twin scandals involving lying about the number of deaths in NY State’s nursing homes and sexually harassing a platoon of aids (and wedding guests) – sees delta as an opportunity to burnish his reputation as a leader. Though we doubt the legislature will return to him the unilateral powers that enabled Cuomo to choke the state’s economy with some of the most restrictive rules in the country.
FDA Signals It Will Expedite Full-Approval Process for COVID Vaccines With vaccination rates plateauing in certain regions of the country as a new COVID wave triggered by the highly infectious Delta variant spreads, the Food and Drug Administration (FDA) has signaled it will expedite the process to fully approve the COVID vaccine. A top agency official said Friday that the Pfizer-BioNTech shot will be under accelerated review to earn the designation. FDA spokesperson Abby Capobianco said the agency is working on “identifying additional resources such as personnel and technological resources from across the agency and opportunities to reprioritize other activities, in order to complete our review to help combat this pandemic surge.” The agency has deployed an “all hands on deck” strategy for this endeavor, Peter Marks, director of the Center for Biologics Evaluation and Research, said in an interview. The Pfizer vaccine has so far been distributed under FDA emergency-use authorization it received in December. The company applied for full approval on May 7. “We recognize that for some, the FDA approval of Covid-19 vaccines may bring additional confidence and encourage them to get vaccinated,” Capobianco said in a statement. “FDA staff will conduct a thorough review process, while balancing the incredible sense of urgency necessary, both of which are needed to ensure that any vaccine that is authorized or approved meets our rigorous standards for safety, effectiveness, and quality.”
Special Guest – Beth Meek
Hour 2 Special Guest – Tracey Stroup
Tracey Stroup has been in the health and wellness industry for over 25 years. She has a B.S. in Exercise and Sports Science from the Pennsylvania State University with a minor in Nutrition. She has also continued her education taking courses in biochemistry, biology and food science. Tracey is a Certified Digestive Health Specialist from the Food Enzyme Institute. She once dreamed of going to medical school but turned down her acceptance to pursue a career in natural health. She completed her designation as a Naturopathic Doctor from Trinity School of Natural Health with additional courses as a Master Herbalist, Iridology and is a Certified Natural Health Professional.
Tracey’s career in Natural Health has been vast. Her first career path was as a personal trainer and quickly advanced to Fitness Director of several gyms. She eventually opened her own personal training studio from 2005 – 2012 where she employed three additional trainers with an average clientele of 200+ clients a week. Upon attaining her natural health designation, Tracey became an instructor for her Alma Mater. During that time she owned a successful natural health practice in her hometown utilizing the trilogy of health approach with each client: mind, body and spirit. Within her practice she co-owned a juice bar and corporate wellness company. Tracey has been the Vice President of Operations for a natural health college establishing curriculum, partnerships with large supplement companies and creating natural health business management strategies for graduates of the program. Tracey was recruited by a leading Biocommunication company as their Vice President of Operations where she designed practitioner software, educational concepts and marketing strategies to promote their software and brand.
The future is bright…
Tracey’s experience and education have now brought her to Nutritional Frontiers. As our Chief Operating Officer, Tracey’s mission is to work with practitioners in the field to create educational opportunities beyond their scope of practice, provide a platform to share their expertise through our new division, Nutritional Frontiers University, and to teach the masses about the value of a foundational living. Tracey works directly with Nutritional Frontiers departments to provide guidance for better operations to enhance the customer experience. She is instrumental in creating new divisions to educate and provide wellness to the consumer populations. Programs like the Nutritional Frontiers University, The 5R System and our new Corporate Wellness division are a few examples of programs introduced since her joining our team.
“I’m truly excited to be part of the Nutritional Frontiers team. This is a company based on education, great products and wonderful people. Together we can unify the industry of medical and natural health professionals under the brand of knowledge and the common goal to make the world healthy again.” Tracey
Cannabinoids as Key Regulators of Inflammasome Signaling: A Current Perspective Inflammasomes are cytoplasmic inflammatory signaling protein complexes that detect microbial materials, sterile inflammatory insults, and certain host-derived elements. Inflammasomes, once activated, promote caspase-1–mediated maturation and secretion of pro-inflammatory cytokines, interleukin (IL)-1β and IL-18, leading to pyroptosis. Current advances in inflammasome research support their involvement in the development of chronic inflammatory disorders in contrast to their role in regulating innate immunity. Cannabis (marijuana) is a natural product obtained from the Cannabis sativa plant, and pharmacologically active ingredients of the plant are referred to as cannabinoids. Cannabinoids and cannabis extracts have recently emerged as promising novel drugs for chronic medical conditions. Growing evidence indicates the potent anti-inflammatory potential of cannabinoids, especially Δ9-tetrahydrocannabinol (Δ9-THC), cannabidiol (CBD), and synthetic cannabinoids; however, the mechanisms remain unclear. Several attempts have been made to decipher the role of cannabinoids in modulating inflammasome signaling in the etiology of chronic inflammatory diseases. In this review, we discuss recently published evidence on the effect of cannabinoids on inflammasome signaling. We also discuss the contribution of various cannabinoids in human diseases concerning inflammasome regulation. Lastly, in the milieu of coronavirus disease-2019 (COVID-19) pandemic, we confer available evidence linking inflammasome activation to the pathophysiology of COVID-19 suggesting overall, the importance of cannabinoids as possible drugs to target inflammasome activation in or to support the treatment of a variety of human disorders including COVID-19.
Fighting the storm: could novel anti-TNFα and anti-IL-6 C. sativa cultivars tame cytokine storm in COVID-19? The main aspects of severe COVID-19 disease pathogenesis include hyper-induction of proinflammatory cytokines, also known as ‘cytokine storm’, that precedes acute respiratory distress syndrome (ARDS) and often leads to death. COVID-19 patients often suffer from lung fibrosis, a serious and untreatable condition. There remains no effective treatment for these complications. Out of all cytokines, TNFα and IL-6 play crucial roles in cytokine storm pathogenesis and are likely responsible for the escalation in disease severity. These cytokines also partake in the molecular pathogenesis of fibrosis. Therefore, new approaches are urgently needed, that can efficiently and swiftly downregulate TNFα, IL-6, and the inflammatory cytokine cascade, in order to curb inflammation and prevent fibrosis, and lead to disease remission. Cannabis sativa has been proposed to modulate gene expression and inflammation and is under investigation for several potential therapeutic applications against autoinflammatory diseases and cancer. Here, we hypothesized that the extracts of novel C. sativa cultivars may be used to downregulate the expression of pro-inflammatory cytokines and pathways involved in inflammation and fibrosis. Initially, to analyze the anti-inflammatory effects of novel C. sativa cultivars, we used a well-established full thickness human 3D skin artificial EpiDermFTTM tissue model, whereby tissues were exposed to UV to induce inflammation and then treated with extracts of seven new cannabis cultivars. We noted that out of seven studied extracts of novel C. sativa cultivars, three (#4, #8 and #14) were the most effective, causing profound and concerted down-regulation of COX2, TNFα, IL-6, CCL2, and other cytokines and pathways related to inflammation and fibrosis. These data were further confirmed in the WI-38 lung fibroblast cell line model. Most importantly, one of the tested extracts had no effect at all, and one exerted effect that may be deleterious, signifying that careful cannabis cultivar selection must be based on thorough pre-clinical studies.
SARS-CoV2 induced respiratory distress: Can cannabinoids be added to anti-viral therapies to reduce lung inflammation? Coronavirus disease-2019 (COVID-19), caused by Severe Acute Respiratory Syndrome coronoavirus-2 (SARS-CoV2) has emerged as a global pandemic, which was first reported in Wuhan, China. Recent reports have suggested that acute infection is associated with a cytokine superstorm, which contributes to the symptoms of fever, cough, muscle pain and in severe cases bilateral interstitial pneumonia characterized by ground glass opacity and focal chest infiltrates that can be visualized on computerized tomography scans. Currently, there are no effective antiviral drugs or vaccines against SARS-CoV2. In the recent issue of BBI, Zhang et al. thoroughly summarized the current status of potential therapeutic strategies for COVID-19. One of them, anti-IL6 receptor (Tocilizumab) antibody, resulted in clearance of lung consolidation and recovery in 90% of the 21 treated patients. Although promising, it has also produced adverse effects like pancreatitis and hypertriglyceridemia, which make it imperative to explore effective alternative anti-inflammatory strategies. Here, we intend to highlight the potential effects of cannabinoids, in particular, the non-psychotropic cannabidiol (CBD), that has shown beneficial anti-inflammatory effects in pre-clinical models of various chronic inflammatory diseases and is FDA approved for seizure reduction in children with intractable epilepsy .